• Explore /
  • Poster
  • / Combination of the Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)/rituximab (R) (BR) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase Ib/II study.

Combination of the Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)/rituximab (R) (BR) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase Ib/II study.

Abstract Poster

Authors

null

Susan Mary O'Brien

University of Texas M. D. Anderson Cancer Center, Houston, TX

Susan Mary O'Brien , Jacqueline Claudia Barrientos , Ian W. Flinn , Paul M. Barr , Jan Andreas Burger , Tasheda Navarro , Danelle Frances James , Eric Hedrick , Jonathan W. Friedberg , Jennifer R. Brown

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2012 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Leukemia, Myelodysplasia, and Transplantation

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Leukemia

Clinical Trial Registration Number

NCT01292135

Citation

J Clin Oncol 30, 2012 (suppl; abstr 6515^)

Abstract #

6515^

Poster Bd #

7

Abstract Disclosures

Similar Posters

First Author: Wojciech Jurczak

First Author: Kerry Anne Rogers

First Author: David S. Hong

First Author: Connie Lee Batlevi